Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Late-Onset Myasthenia Graivs,A Changing Scene
Arch Neurol 56:25-27, Aarli,J.A., 1999
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
IV Immunoglobulin in Patients With Myasthenia Gravis
Neurol 68:837-841,803, Zinman,L., et al, 2007
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Race, Sex, and Puberty Influence Onset, Severity, and Outcome in Juvenile Myasthenia Gravis
Neurol 44:1208-1214, Andrews,P.I.,et al, 1994
Total Body Irradiation for Myasthenia Gravis:A Long-Term Follow-up
Neurol 43:2215-2221, Durelli,L.,et al, 1993
Ocular Myasthenia Gravis
J Natl Med Assoc 85:681-684, March,G.A.&Johnson,J.N., 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984
Prednisone Use in Concurrent Autoimmune Diseases
Arch Neurol 36:103-106, Harati,Y.,et al, 1979
Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978
Function of Circulating Antibody to Acetylcholine Receptor in Myasthenia Gravis:Investigation by Plasma Exchange
Neurol 28:266, Newsom-Davis,J.,et al, 1978
Plasmapheresis & Immunosuppressive Drug Therapy in Myasthenia Gravis
NEJM 297:1134, Dau,P.C.,et al, 1977
Long-term Administration of Corticosteroids in Myasthenia Gravis
Neurol 26:729, Mann,J.D.,et al, 1976